explore -WSS

explore

author：knowledge 2025-10-03 00:39:20 - browse：52647

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Roche drug slashes death risk in early

WSS

How AI can help patients find reliable information about doctors

Stroke deaths set to near 10 million globally by 2050

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

CZI to create biohub to build anti

Study on Amgen’s bispecific immunotherapy produces positive data

What to expect at HLTH 2023, the health care industry conference

entertainment

explore

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Stroke deaths set to near 10 million globally by 2050

Hollywood unions extend contract negotiations for actors

Colorectal cancer study finds potential in overlooked immune cell

As demand for Covid shots wanes, Moderna seeks its next success

Phenylephrine and the overlooked value of the placebo effect

As demand for Covid shots wanes, Moderna seeks its next success

Analysis of telehealth claims data suggest service duplication

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

hotspot

J&J lung cancer data amount to new salvo against AstraZeneca

Why Charlie Gard's case is so disturbing to Americans

A virus, fished out of a lake, may have saved a man’s life

AI can decode, harness the power of the humane immune system

Colorectal cancer study finds potential in overlooked immune cell

CZI to create biohub to build anti

leisure time

entertainment

focus

hotspot